Literature DB >> 11104793

Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.

M Sumitomo1, R Shen, M Walburg, J Dai, Y Geng, D Navarro, G Boileau, C N Papandreou, F G Giancotti, B Knudsen, D M Nanus.   

Abstract

Neutral endopeptidase 24.11 (NEP, CD10) is a cell-surface enzyme expressed by prostatic epithelial cells that cleaves and inactivates neuropeptides implicated in the growth of androgen-independent prostate cancer (PC). NEP substrates such as bombesin and endothelin-1 induce cell migration. We investigated the mechanisms of NEP regulation of cell migration in PC cells, including regulation of phosphorylation on tyrosine of focal adhesion kinase (FAK). Western analyses and cell migration assays revealed an inverse correlation between NEP expression and the levels of FAK phosphorylation and cell migration in PC cell lines. Constitutively expressed NEP, recombinant NEP, and induced NEP expression using a tetracycline-repressive expression system inhibited bombesin- and endothelin-1-stimulated FAK phosphorylation and cell migration. This results from NEP-induced inhibition of neuropeptide-stimulated association of FAK with cSrc protein. Expression of a mutated catalytically inactive NEP protein also resulted in partial inhibition of FAK phosphorylation and cell migration. Coimmunoprecipitation experiments show that NEP associates with tyrosine-phosphorylated Lyn kinase, which then binds the p85 subunit of phosphatidylinositol 3-kinase (PI3-K) resulting in an NEP-Lyn-PI3-K protein complex. This complex competitively blocks FAK-PI3-K interaction, suggesting that NEP protein inhibits cell migration via a protein-protein interaction independent of its catalytic function. These experiments demonstrate that NEP can inhibit FAK phosphorylation on tyrosine and PC cell migration through multiple pathways and suggest that cell migration which contributes to invasion and metastases in PC cells can be regulated by NEP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104793      PMCID: PMC381465          DOI: 10.1172/JCI10536

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

Review 1.  Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer.

Authors:  J B Nelson; M A Carducci
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

2.  Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration.

Authors:  H R Reiske; S C Kao; L A Cary; J L Guan; J F Lai; H C Chen
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

3.  Macrophage stimulating protein-induced epithelial cell adhesion is mediated by a PI3-K-dependent, but FAK-independent mechanism.

Authors:  A Danilkovitch; A Skeel; E J Leonard
Journal:  Exp Cell Res       Date:  1999-05-01       Impact factor: 3.905

4.  Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo.

Authors:  G Cutrona; N Leanza; M Ulivi; G Melioli; V L Burgio; G Mazzarello; G Gabutti; S Roncella; M Ferrarini
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

5.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF.

Authors:  N Prenzel; E Zwick; H Daub; M Leserer; R Abraham; C Wallasch; A Ullrich
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

6.  High frequency of adhesion defects in B-lineage acute lymphoblastic leukemia.

Authors:  T B Geijtenbeek; Y van Kooyk; S J van Vliet; M H Renes; R A Raymakers; C G Figdor
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

7.  Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells.

Authors:  L P Eberl; O Valdenaire; V Saintgiorgio; J F Jeannin; L Juillerat-Jeanneret
Journal:  Int J Cancer       Date:  2000-04-15       Impact factor: 7.396

8.  Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway.

Authors:  D Q Zheng; A S Woodard; M Fornaro; G Tallini; L R Languino
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

9.  Association of CD10/neutral endopeptidase 24.11 with membrane microdomains rich in glycosylphosphatidylinositol-anchored proteins and Lyn kinase.

Authors:  P Angelisová; K Drbal; V Horejsí; J Cerný
Journal:  Blood       Date:  1999-02-15       Impact factor: 22.113

10.  Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways.

Authors:  A B Satterthwaite; C A Lowell; W N Khan; P Sideras; F W Alt; O N Witte
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more
  41 in total

Review 1.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  The Src kinase Yes is activated in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters, but not pancreatic growth factors, which stimulate its association with numerous other signaling molecules.

Authors:  Veronica Sancho; Bernardo Nuche-Berenguer; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2012-05-19

Review 3.  Neural regulation of hematopoiesis, inflammation, and cancer.

Authors:  Maher Hanoun; Maria Maryanovich; Anna Arnal-Estapé; Paul S Frenette
Journal:  Neuron       Date:  2015-04-22       Impact factor: 17.173

4.  Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.

Authors:  Sven Gunia; Knut Albrecht; Stefan Koch; Thomas Herrmann; Thorsten Ecke; Volker Loy; Jörg Linke; Michael Siegsmund; Matthias May
Journal:  World J Urol       Date:  2008-04-05       Impact factor: 4.226

5.  Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer.

Authors:  Sharanjot Saini; Shahana Majid; Varahram Shahryari; Z Laura Tabatabai; Sumit Arora; Soichiro Yamamura; Yuichiro Tanaka; Rajvir Dahiya; Guoren Deng
Journal:  Mol Cancer Ther       Date:  2014-05-09       Impact factor: 6.261

6.  Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells.

Authors:  Ya-Min Fu; Zu-Xi Yu; Huimin Lin; Xing Fu; Gary G Meadows
Journal:  J Cell Physiol       Date:  2008-10       Impact factor: 6.384

7.  FYN is overexpressed in human prostate cancer.

Authors:  Edwin M Posadas; Hikmat Al-Ahmadie; Victoria L Robinson; Ramasamy Jagadeeswaran; Kristen Otto; Kristen E Kasza; Maria Tretiakov; Javed Siddiqui; Kenneth J Pienta; Walter M Stadler; Carrie Rinker-Schaeffer; Ravi Salgia
Journal:  BJU Int       Date:  2008-10-16       Impact factor: 5.588

8.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

9.  Stage-specific modulation of neprilysin and aminopeptidase N in the limbic system during kindling progression.

Authors:  Patricia de Gortari; Miguel Angel Vargas; Adrián Martínez; Arlene I García-Vázquez; Rosa María Uribe; Lucía Chávez-Gutiérrez; Víctor Magdaleno; Guy Boileau; Jean-Louis Charlí; Patricia Joseph-Bravo
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

10.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.